Purpura Fulminans (PF)
Purpura fulminans (PF) is a rapidly progressing thrombotic disorder that is frequently fatal. Our company is committed to developing cutting-edge diagnostics and therapeutics for the management of purpura fulminans. As your reliable partner in purpura fulminans research, we offer streamlined and comprehensive solutions to meet all your scientific research requirements.
Introduction to Purpura Fulminans
Purpura fulminans is a rare and life-threatening condition marked by rapid skin bleeding and necrosis. It is characterized by the formation of blood clots and the collapse of dermal blood vessels, leading to compromised tissue perfusion and oxygen supply. This can result in tissue and organ dysfunction, ultimately leading to organ failure. Purpura fulminans is an extremely rare condition, with an estimated occurrence of approximately 1 in 1,000,000 live births.
Fig. 1 Symptoms and diagnosis of idiopathic purpura fulminans. (Theron, Alexandre, et al., 2022)Pathogenesis of Purpura Fulminans
Purpura fulminans primarily stems from bacterial infections, wherein the body's immune response is triggered, leading to an exaggerated coagulation process. Excessive clot formation, coupled with the collapse of blood vessels, hampers blood flow to the skin and adjacent tissues. The bacteria associated with purpura fulminans include the following:
- Meningococcus (Neisseria meningitidis)
- Gram-negative bacilli
- Staphylococcus
- Streptococcus
- Rickettsia organisms
Strategies of Purpura Fulminans Therapy Development
Antibacterial Therapy
Bacterial infection plays an important role in the pathogenesis of purpura fulminans. Targeting these bacterial pathogens using specific antibiotics such as penicillins, cephalosporins, fluoroquinolones, and macrolides is critical to control infection and prevent progression of purpura fulminans.
Inhibit Coagulation
Disseminated intravascular coagulation (DIC) is commonly associated with purpura fulminans. In order to prevent excessive clot formation and improve blood flow while minimizing tissue damage, anticoagulants such as heparin and warfarin are frequently utilized.
Immunomodulatory
In purpura fulminans, where an excessive immune response occurs, immunomodulatory agents like intravenous immunoglobulins (IVIG) can be employed to regulate the immune system and mitigate immune-mediated tissue damage.
Our Services
With years of extensive involvement in rare disease research, our company boasts a highly skilled team and vast expertise. We harness state-of-the-art technology to drive the development of innovative diagnostic tools, enabling early detection of purpura fulminans. By establishing animal models and conducting in-depth investigations into purpura fulminans pathogenesis and targets, we advance therapeutic drug development.
Our Research Platforms
Our Services
Animal Models of Purpura Fulminans
| Induced Models | |
|---|---|
| At our company, we specialize in creating animal models that simulate purpura fulminans-like symptoms. Our scientists have successfully developed models using methods such as bacterial infection, administration of bacterial toxins, or coagulation factor manipulation. These models accurately replicate essential pathological characteristics observed in human purpura fulminans, including skin necrosis, coagulation abnormalities, and immune dysregulation. | |
| Optional Species | Mice, Rats, Rabbits, Non-Human Primates (Baboons and Macaques), Others |
No matter what stage of research you are at, we can provide you with corresponding research services. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Theron, Alexandre, et al. "Idiopathic purpura fulminans associated with anti-protein S antibodies in children: a multicenter case series and systematic review." Blood Advances 6.2 (2022): 495-502.
- Brozyna, Jeremy R., et al. "Acute purpura fulminans—a rare cause of skin necrosis: A single‐institution clinicopathological experience." Journal of Cutaneous Pathology 47.11 (2020): 1003-1009.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.